WCG Wealth Advisors LLC Increases Stock Holdings in Medtronic PLC $MDT

WCG Wealth Advisors LLC increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 150.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,780 shares of the medical technology company’s stock after buying an additional 40,683 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Medtronic were worth $6,511,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership lifted its holdings in shares of Medtronic by 2.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after buying an additional 31,314 shares during the period. CSM Advisors LLC grew its position in shares of Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after purchasing an additional 33,167 shares in the last quarter. SageView Advisory Group LLC grew its position in Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after acquiring an additional 15,062 shares during the period. Madison Asset Management LLC grew its position in Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after acquiring an additional 25,527 shares during the period. Finally, Bleakley Financial Group LLC boosted its position in shares of Medtronic by 17.8% during the third quarter. Bleakley Financial Group LLC now owns 87,313 shares of the medical technology company’s stock worth $8,316,000 after buying an additional 13,177 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic topped Q4 expectations with revenue of $9.81 billion and adjusted EPS of $1.55, supported by strong demand in cardiovascular devices and standout growth in Cardiac Ablation Solutions, which jumped 78% globally. Article Title
• Positive Sentiment: Management said FY2026 delivered Medtronic’s strongest annual revenue growth in 10 years, while FY2027 guidance calls for 6.75% to 7.25% organic revenue growth and EPS of $5.90 to $6.00, reinforcing the company’s growth outlook. Article Title
• Positive Sentiment: Medtronic also raised its quarterly dividend to $0.72 per share, a signal of confidence in cash flow and shareholder returns. Article Title
• Positive Sentiment: The company highlighted momentum in its Hugo robotic surgery platform and new strategic investments in cardiac ablation technologies, which could support longer-term growth and product expansion. Article Title
• Neutral Sentiment: Wall Street reacted positively even though some investors remain focused on tariff pressures, margin headwinds, and FY2027 EPS guidance that came in slightly below the consensus estimate. Article Title

Medtronic Stock Up 5.9%

Medtronic stock opened at $78.09 on Thursday. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock has a market cap of $100.25 billion, a PE ratio of 21.75, a P/E/G ratio of 1.76 and a beta of 0.58. The stock’s fifty day moving average is $81.67 and its two-hundred day moving average is $92.21.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period last year, the firm earned $1.62 earnings per share. Medtronic’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.54 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.7%. This is an increase from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. Medtronic’s payout ratio is presently 79.11%.

Analysts Set New Price Targets

MDT has been the topic of several analyst reports. Evercore set a $106.00 price objective on Medtronic and gave the company an “outperform” rating in a research note on Thursday, April 9th. Truist Financial reduced their price objective on Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Mizuho reduced their price objective on Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday. The Goldman Sachs Group set a $84.00 price target on Medtronic and gave the company a “neutral” rating in a research note on Thursday, May 21st. Finally, Jefferies Financial Group restated a “hold” rating and issued a $88.00 price target on shares of Medtronic in a research note on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $102.76.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).